These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383 [TBL] [Abstract][Full Text] [Related]
28. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027 [TBL] [Abstract][Full Text] [Related]
29. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400 [TBL] [Abstract][Full Text] [Related]
30. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. van der Sijde F; Homs MYV; van Bekkum ML; van den Bosch TPP; Bosscha K; Besselink MG; Bonsing BA; de Groot JWB; Karsten TM; Groot Koerkamp B; Haberkorn BCM; Luelmo SAC; Mekenkamp LJM; Mustafa DAM; Wilmink JW; van Eijck CHJ; Vietsch EE; On Behalf Of The Dutch Pancreatic Cancer Group Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681562 [TBL] [Abstract][Full Text] [Related]
31. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. Park G; Park JK; Son DS; Shin SH; Kim YJ; Jeon HJ; Lee J; Park WY; Lee KH; Park D Sci Rep; 2018 Aug; 8(1):11631. PubMed ID: 30072705 [TBL] [Abstract][Full Text] [Related]
32. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053 [TBL] [Abstract][Full Text] [Related]
33. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344 [TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125 [TBL] [Abstract][Full Text] [Related]
35. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290 [TBL] [Abstract][Full Text] [Related]
36. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932 [TBL] [Abstract][Full Text] [Related]
37. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397 [TBL] [Abstract][Full Text] [Related]
38. Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging. Edland KH; Tjensvoll K; Oltedal S; Dalen I; Lapin M; Garresori H; Glenjen N; Gilje B; Nordgård O Mol Oncol; 2023 Sep; 17(9):1857-1870. PubMed ID: 37341038 [TBL] [Abstract][Full Text] [Related]
39. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study. Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751 [TBL] [Abstract][Full Text] [Related]
40. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Christenson ES; Lim SJ; Durham J; De Jesus-Acosta A; Bever K; Laheru D; Ryan A; Agarwal P; Scharpf RB; Le DT; Wang H Cancer Res Commun; 2022 Nov; 2(11):1418-1425. PubMed ID: 36970054 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]